John Rim, the company’s former executive vice-president, has been named its new president and CEO.
Samsung Biologics announced on Dec. 16, 2020 that John Rim, the company’s former executive vice-president, has been named its new president and CEO.
Rim has more than 30 years of experience in the biopharmaceutical industry and previously held senior global leadership roles at Genentech/Roche and Astellas Pharmaceuticals after starting his career at Booz, Allen & Hamilton as a management consultant, Samsung said in a company press release.
“I am deeply grateful and excited by the opportunity to lead Samsung Biologics into the next decade,” said Rim in the press release. “This is an extraordinary company, unparalleled in its phenomenal growth and dedication to client satisfaction, made possible by the company’s unrelenting vision and passion, and business execution by great people whom I will have the privilege to lead as CEO.”
Source: Samsung
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.